Cipla Accused Of Promoting Generic For Unauthorized Use
This article was originally published in PharmAsia News
India's drug controller general has asked Cipla to repond to a distributor's charge Cipla falsely promoted a cancer drug, the generic Erlocip (erlotinib hydrochloride). Distributor Taksal Pharma carries Roche Scientific products such as its Tarceva, of which Erlocip is a generic. The distributor complained Cipla promotional literature suggests using Erlocip to treat four kinds of cancers, when the branded version has been approved in India only for non small-cell lung cancer and pancreatic cancer, and the generic only for the former. (Click here for more
You may also be interested in...
Infographic timeline looks at key moments in the history of vaccine development, from the first vaccine against smallpox to the polio field trial involving 1.8 million children to the flurry of vaccines created by ‘the scientist who saved more lives than all other scientists combined.’
Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.